Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Zn-Telomir

Small molecule · Inhibitor of iron-dependent KDM enzymes (lysine demethylases) · developed by Telomir Pharmaceuticals

Phase 1/2 Most advanced trial
TELO Developer
1 Registered trials

What is Zn-Telomir?

Zn-Telomir is an oral small molecule that inhibits iron-dependent KDM enzymes, reducing tumor DNA methylation and killing cancer cells in an iron-dependent manner. It is studied in triple-negative breast cancer, including advanced and metastatic disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
iron-dependent KDM enzymes (lysine demethylases)
Mechanism
Inhibitor of iron-dependent KDM enzymes (lysine demethylases)
Pathways
DNA methylation, iron homeostasis, iron-dependent cell death
Therapy area
Oncology
Developer
Telomir Pharmaceuticals, Inc. (TELO)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07581314 Phase 1/2 Triple-Negative Breast Cancer (TNBC) Not yet recruiting TELO

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Triple-Negative Breast CancerMetastatic Triple-negative Breast CancerTriple-Negative Breast Cancer (TNBC)

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the TELO page.

Follow TELO, the company behind Zn-Telomir

See TELO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

TELO catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.